Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved the use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Weis, Luiza N., Tolaney, Sara M., Barrios, Carlos H., Barroso-Sousa, Romualdo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437983/
https://www.ncbi.nlm.nih.gov/pubmed/34518552
http://dx.doi.org/10.1038/s41523-021-00328-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437983/
https://www.ncbi.nlm.nih.gov/pubmed/34518552
http://dx.doi.org/10.1038/s41523-021-00328-3

Ejemplares similares